PureTech-founded Seaport outlines GlyphAgo trial timeline
Seaport said it plans to start a Phase 2/3 trial of GlyphAgo in the first half of 2027 and expects topline data by the end of 2028. It also said topline data from the Phase 2a trial is anticipated in early 2028.
Story updates
05:00:58 PM UTC
SquawkNews
Seaport Therapeutics reported Phase 1 PK data for GlyphAgo showing a 6.8-fold increase in agomelatine bioavailability and 10-fold lower PK variability vs unmodified drug. Phase 2/3 in GAD is planned for H1 2027; Phase 2a in GAD with sleep disturbance is underway.Material DetailsContext by AI Analys…